On June 5, 2025, Sarepta Therapeutics held its annual meeting where stockholders approved amendments increasing share limits under its 2018 Equity Incentive Plan by 4.3 million shares and its Employee Stock Purchase Plan by 300,000 shares, alongside the election of directors and approval of executive compensation.